IBD Evidence

Cóireáil

Comhoiriúnachtaí le cógaisíocht agus teiripeacha

Ar an gcéad uair, tá freagraí mheitheolaíochta ar an gceist chomhoiriúnach — cén druga, ní nach bhfuil druga — ann.

Updated 2 min read 26 citations Evidence strength 5/5

Snáithe endasóscópach le haghaidh polypectomy gastrointestinal uachtarach agus colónach
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Cad a tháinig chun bheith

Ar feadh dhá deich mbliana, bhí an bonn cruthúnas drug-versus-placebo, a dúirt le cliniceoirí go n-oibríonn biologics agus ní raibh aon rud a roghnaigh. D'athraigh anailís líonra mheitheolaíochta sin trí chomhoiriúnachtaí comhoibrithe a úsáid chun rangú na dteiripí go doléite [1][4].

Is é an toradh praiticiúil go bhfuil sé indéanta anois smaoineamh ar rogha an chéad líne seachas é a chur i bhfeidhm go huathoibríoch, agus tá difríochtaí idir gníomhairí ar induction i gcomparáid le cothabháil, agus ar éifeachtúlacht i gcomparáid le sábháilteacht, infheicthe.

Éifeachtúlacht chomhoiriúnach na dteiripí chun cinn

Na ranganna

Ranganna teiripe chun cinn i IBD
RangMeicníochtNótaí
Fritháirge TNFBlocann fachtóir necrosis tumoideach alphaAn taifead is faide; is é an t-immunogenicity an príomhlaige.
Fritháirge intígrínBlocann tráchtáil leucócítí chuig an gutRogha guta, mar sin sábháilteacht chórasúil fabhrach
Anti-IL-12/23 agus anti-IL-23Blocann comharthaíocht interleukinPróifíl láidir éifeachtúlachta agus sábháilteachta i gcomparáid le déanaí
Inhibítóirí JAKMóilín beag, comharthaíocht laistigh de cheallaOral agus tapa; foláireamh cardiovascular agus thrombóis
Modhálaithe S1PSequesters lymphocytes i gcnámha limfeOral; níos nuaí, sonraí níos lú fadtéarmacha

Cóireáil chun sprioc, ní chun comharthaí

Is é an t-athrú is tábhachtaí i mbainistíocht IBD ná go bhfuil comharthaí ina n-aistritheoirí bochta do dhíobháil. Mothaíonn daoine go maith le díobháil gníomhach agus mothaíonn siad go dona i gcuimhne. Mar sin, tá treoir reatha na hEorpa dírithe ar mharcóirí oibiachtúla — calprotectin feacal, leigheas endoscópach — seachas conas a thuigeann an t-othar a mhothú.

Is é seo freisin an freagra ar an gceist a bhaineann le bia a raised ar an leathanach aiste bia: níor cóireáil an ghalar éard atá i gceist le hidirghníomhú a fheabhsaíonn comharthaí gan feabhas a chur ar mharcóirí oibiachtúla.

Nuair nach leor druga amháin

Tugadh measúnú ar chóireáil dhúbailte biologic nó cóireáil beaga-móilín comhcheangailte do ghalar frithsheasmhach [3]. Tá sé fós ina chinneadh speisialtóra le bonn cruthúnas teoranta, agus is é an áit a bhfuil an obair shingle-ceall a charachtaríonn éagsúlacht freagartha [2] is mó a athróidh cleachtas — trí thuar cén meicníocht atá le sprioc a bhaint amach i gconradh le hothar áirithe seachas é a fháil trí theip seicheamhach.

Radharc sráide ar fhoirgneamh na poitigéara sa stáisiún i Bautzen, an Ghearmáin
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

Ceisteanna coitianta

Cén biologic atá is fearr?
Tugann anailísí líonra mheitheolaíochta rangú orthu anois [1][4], agus braitheann an rogha cheart ar shuíomh ghalair, déine, gnéithe extraintestinal agus do tholerans riosca féin.
An féidir liom stop a chur nuair a bhíonn mé i gcuimhne?
Tugann tarraingt riosca mór athraithe. Is cinneadh é a dhéanamh le do ghrúpa, bunaithe ar mharcóirí oibiachtúla seachas conas a mhothaíonn tú.
An bhfuil biologics contúirteach?
Tugann siad rioscaí fíor, go príomha ionfhabhtú. Tugann ionfhabhtú neamhchóireáilte riosca freisin, agus is é an comparáid idir dhá rioscaí seachas i gcoinne nialas.
Cad é calprotectin?
Mharcóir stól do dhíobháil intestinal. Is é an bealach a monatóireacht a dhéantar ar "chóireáil chun sprioc" i ndáiríre.
An cruthúnas atá taobh thiar den leathanach seo Barra chruinnithe ag taispeáint comhoibriú na 20 foilseacháin atá luaite ar an leathanach seo de réir cineál staidéir. 24meta-analysis (24)
20 foilsithe, 2015–2025. Is bunús mórán faireachais é seo. Is féidir leis a bhunú go dtarlaíonn rudaí le chéile; ní féidir leis a shocrú cé acu a chúsaíonn an ceann eile. Téarma: liosta luaiteanna féin an leathanach seo, thíos.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  2. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  3. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  4. ACG Clinical Guideline Update: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701556
  5. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Afzali A, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701562
  6. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders Barnes EL, Agrawal M, Syal G, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38128971Full text
  7. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review Hashash JG, Elkins J, Lewis JD, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38276922
  8. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  9. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Singh S, Loftus EV Jr, Limketkai BN, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 39572132Full text
  10. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment Adamina M, Minozzi S, Warusavitarne J, et al. · Journal of Crohn's & colitis · 2024 · Clinical guideline DOIPubMed 38878002
  11. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  12. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  13. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  14. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  15. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  16. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  17. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  18. [ESPEN guideline: Clinical nutrition in inflammatory bowel disease] Bischoff SC, Escher J, Hébuterne X, et al. · Nutricion hospitalaria · 2022 · Clinical guideline DOIPubMed 35014851
  19. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  20. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  21. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  22. ACG Clinical Guideline: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2019 · Clinical guideline DOIPubMed 30840605
  23. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Isaacs KL, et al. · The American journal of gastroenterology · 2018 · Clinical guideline DOIPubMed 29610508
  24. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition Turner D, Ruemmele FM, Orlanski-Meyer E, et al. · Journal of pediatric gastroenterology and nutrition · 2018 · Clinical guideline DOIPubMed 30044357
  25. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  26. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text

This page was translated automatically from English. The citations and numbers are unchanged. Read the English original if anything reads oddly. Read the English original